Lupisit DM 10mg/500mg/100mg Tablet

Metformin, a biguanide, primarily reduces hepatic gluconeogenesis and enhances peripheral glucose uptake, contributing to improved insulin sensitivity. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin hormone levels, which enhance glucose-dependent insulin secretion and suppress glucagon release. The combined action of these agents provides effective glycemic control, addressing multiple pathophysiological defects in type 2 diabetes.

Lupisit DM is typically prescribed as part of a comprehensive treatment plan including diet and exercise. Caution is advised in patients with renal impairment, hepatic dysfunction, or risk factors for lactic acidosis. Common adverse effects may include gastrointestinal disturbances, urinary tract infections, and hypoglycemia when used with other antidiabetic agents. Regular monitoring of blood glucose, renal function, and patient adherence is essential to optimize therapeutic outcomes and minimize risks.